Accès ouvert
2025
article
OpenAlex
Ricquee Gonzalez‐Green, Trisha L. Walsh, Claire M Erickson, Nellie M. High et autres
BACKGROUND: Blood biomarkers are becoming pivotal tools in the diagnosis and management of neurodegenerative diseases, such as Alzheimer's disease (AD). The leading blood biomarker for AD, pTau-217, demonstrates high sensitivity and specificity for identifying individuals at risk for AD dementia, or who …
us, se
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Christopher T. Brown, Jessica Enos, Carolyn M. Langlois, Trisha L. Walsh et autres
BACKGROUND: The Alzheimer's Prevention Initiative (API)Generation Program studies were sponsored by Novartis and Amgen, in partnership with Banner Alzheimer's Institute and with support from the U.S. National Institute on Aging and Banner. API Generation Study 1 (NCT0256551) was designed to evaluate cognitive, …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Marisa N. Denkinger, Alpana Singh, James Liu, Kari Dieckhoff et autres
BACKGROUND: Plasma biomarkers are increasingly recognized for identifying Alzheimer's disease (AD) pathology but biomarkers for other common co-occurring pathologies (e.g., TDP-43, alpha-synuclein) are needed. Limited in vivo gold standards for these pathologies limit biomarker discovery to clinical assessments, which lack the specificity …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Angela R. Bradbury, Brian L. Egleston, Elisabeth Wood, Jason Karlawish et autres
BACKGROUND: APOE genotyping is increasingly important to identify candidates eligible for Alzheimer's prevention trials. Such testing is also now commonplace for patients considering new anti-amyloid treatments, given that APOE4 carriers are at elevated risk for treatment side effects. Data to inform best …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Catarina Tristão‐Pereira, David Fernando Aguillón Niño, Ana Y. Baena, Natalia Londono et autres
Abstract Background Cerebral glucose hypometabolism, measured with 18 F‐fluorodeoxyglucose (FDG) PET, is a hallmark of Alzheimer's disease (AD). While FDG‐PET changes are highly effective at differentiating dementia types, the pathological bases for metabolic changes are complex. Hypometabolism is often assumed to reflect …
us, co, be
(code pays fourni par la source)